Influenza Prevention Clinical Trial
Official title:
A Random, Double -Blind, Placebo Control Phase Ⅰ Trail to Evaluate the Safety and Immunogenicity of Live Attenuated Influenza Vaccine in 3-59y Healthy People
Live Attenuated freeze-dried Influenza Vaccine has been licensed for use in 2020 (Approval No.S20200002), the sponsor of this research submitted an new application for non freeze-dried Live Attenuated Influenza Vaccine in 2021. The main objective of phase Ⅰ trail is to evaluate the safety of LAVI(non freeze-dried). The secondary objective is to evaluate the immunogenicity of LAVI(non freeze-dried).
Totally 160 health people aged 3-59 years old will be divided into two age group, containing 80 in 18-59 years old and 80 in 3-19 years old. All subjects will receive vaccination either LAVI or placebo in a ratio of 3:1. All subjects will be collected any adverse events within 30 days and any serious adverse events within 6 months for safety evaluation. All subjects will be collected blood sample and nasopharyngeal swab for immunogenicity evaluation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06280144 -
Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine
|
Phase 4 | |
| Active, not recruiting |
NCT05901636 -
A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02713061 -
A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult Participants
|
Phase 2 | |
| Not yet recruiting |
NCT05284851 -
The Safety and Immunogenicity Evaluation of Live Attenuated Influenza Vaccine
|
Phase 2 |